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ABSTRACT 
The molecular alterations of pancreatic acinar cell carcinomas (ACCs) and mixed acinar-
neuroendocrine carcinomas (MANECs) are not completely understood and the possible role of c-
MYC amplification in tumor development, progression, and prognosis is not known. We have 
investigated c-MYC gene amplification in a series of 35 ACCs and 4 MANECs to evaluate its 
frequency and a possible prognostic role. Gene amplification was investigated using interphasic 
FISH analysis simultaneously hybridizing c-MYC and the centromere of chromosome 8 probes. 
Protein expression was immunohistochemically investigated using a specific monoclonal anti-c-
myc antibody. 20 cases had clones with different polysomies of chromosome 8 in absence of c-
MYC amplification, 5 cases had one amplified clone and other clones with chromosome 8 
polysomy, while the remaining 14 cases were diploid for chromosome 8 and lacked c-MYC 
amplification. All MANECs showed c-MYC amplification and/or polysomy which were observed in 
54% pure ACCs. Six cases (15.3%) showed nuclear immunoreactivity for c-myc but only 4/39 cases 
showed simultaneous c-MYC amplification/polysomy and nuclear protein expression. c-myc 
immunoreactivity as well as c-MYC amplification and/or chromosome 8 polysomy were not 
statistically associated with prognosis. Our study demonstrates that a subset of ACCs show c-MYC 
alterations including gene amplification and chromosome 8 polysomy. Although they are not 
associated with a different prognostic signature, the fact that these alterations are present in all 
MANECs suggests a role in the acinar-neuroendocrine differentiation possibly involved in the 
pathogenesis of MANECs. 
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INTRODUCTION 
Acinar cell carcinomas (ACCs) of the pancreas are a heterogeneous group of cancers 
showing different morphological features and clinical presentations [1]. In addition, about 10-20% 
of cases showing a significant neuroendocrine component (> 30% of the tumor burden) are 
defined mixed acinar-neuroendocrine carcinomas (MANECs). Together with mixed ductal-
neuroendocrine carcinomas, they belong to the group of mixed neuroendocrine/non-
neuroendocrine neoplasms (MiNENs) [2, 3]. Approximately 50% of ACCs/MANECs are metastatic 
at the time of diagnosis and about 40% of cases recur as local and/or metastatic disease after 
surgical resection [4, 5]. The prognosis is poor with 5-year survival rates ranging between 25 and 
50% without difference between ACCs and MANECs [5]. Although several attempts have been 
made to search for morphological, immunohistochemical, and molecular prognostic factors, tumor 
stage still seems to be the best prognosticator in resectable cases [5]. 
Our knowledge on molecular alterations of ACCs has been greatly expanded in the last 
years and several molecular alterations involved in tumor development and progression have 
been recently identified [1]. Some of them are typical of ACCs, like alterations in the APC/β-
catenin pathway and fusion in RAF genes [6, 7], while others involve genes (i.e. TP53 and BRCA2) 
which play a crucial role in the development and progression of a wide spectrum of different 
cancers [1]. Interestingly, recently published data have suggested that some molecular alterations, 
like those involving TP53, may identify ACC subtypes showing a more aggressive behavior [8]. 
It has been recently reported that about 17% of ACCs show c-MYC amplification, but the 
prognostic role of this alteration remains to be clarified [9]. The oncogene c-MYC is a transcription 
factor implicated in about one-third of human malignancies by promoting tumor growth 
increasing DNA replication and transcription, protein synthesis, cellular metabolism and 
proliferation [10]. c-MYC overexpression is frequently associated with poor clinical outcome [11] 
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and it has been demonstrated that c-MYC plays a pivotal role in the molecular mechanisms 
underlying the aggressiveness of pancreatic ductal adenocarcinoma [10, 11]. 
 In the present study, we have investigated c-MYC gene amplification in a series of 39 
pancreatic ACCs/MANECs in order to evaluate its frequency and a possible prognostic role. 
 
 
MATERIALS AND METHODS 
Cases 
Thirty-nine cases were selected from our previously-reported series of 62 well 
characterized pancreatic ACCs [5]. Tumor selection mainly depended on the availability of 
sufficient material to perform immunohistochemical and FISH analyses together with complete 
clinical information. The main clinico-pathologic characteristics are summarized in Table 1. All 
tissues were fixed in buffered formalin (formaldehyde 4% w/v and acetate buffer 0.05M) and 
routinely processed to paraffin wax. 
 
Immunohistochemistry 
For immunohistochemistry, 3µm-thick sections were mounted on poly-L-lysine coated 
slides, deparaffinized and hydrated through graded alcohols to water. After endogenous 
peroxidase activity inhibition, performed by dipping sections in 3% hydrogen peroxide for 10 
minutes, incubation with primary rabbit monoclonal anti-c-myc antibody (Y69, Abcam, Cambridge, 
UK) was carried out at 4°C for 18–20 hours, followed by the avidin-biotin complex (ABC) 
procedure. Immunoreactions were developed using 0.03% 3,3’diaminobenzidine 
tetrahydrochloride and then sections were counterstained with Harris’ hematoxylin. 
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Fluorescence in situ hybridization (FISH) 
Interphasic FISH analysis was performed on 3-4μm-thick sections used for conventional 
histologic examination as reported in the guidelines of the European Cytogeneticists Association 
[13] and the cytogenetic interpretation of data agrees with the International System for human 
Cytogenetic Nomenclature (ISCN) [14]. FISH analysis was performed using direct viewing on a 
standard fluorescence microscope at ×100 magnification. FISH results were evaluated on 
representative areas of each tumor identified on hematoxylin and eosin stained slides. To ensure a 
representative sample and to permit an assessment of the extent of tumor heterogeneity, c-MYC 
amplification and chromosome 8 polysomies were scored in more than 200 interphasic nuclei 
from at least 5 to 8 separate areas of each tumor by two independent operators (BB and MGT). 
Only experiments with 90% hybridization efficiency were considered. c-MYC amplification was 
investigated simultaneously hybridizing c-MYC (red signal) and the centromere of chromosome 8 
(green signal) probes (Zytolight SPEC MYC/CEN8 Dual Color Probe, Zytovision GmbH, 
Bremerhaven, Germany). Cases were defined as amplified when the ratio (R) between red (c-MYC) 
and green (CEN8) signals was >2.0. Cases were defined as polysomic for chromosome 8 when at 
least 20% of neoplastic cells showed three or more copies of CEN8 signals (green signals). 
 
Statistical analysis 
Comparisons of continuous data were performed using Student’s t tests and discrete 
variables were compared with χ2 test or Fisher’s exact test. Univariate survival analysis was 
performed using Kaplan–Meier curves and log-rank test. Data were statistically analyzed using 
MedCalc Version 12.5.0.0 and GraphPad Prism Version 5.00 softwares and p value <0.05 was 
considered significant. 
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RESULTS 
ACCs and MANECs were more frequently observed in males (29 cases) than in females (10 
cases) and the average age at diagnosis was 59.7 years (range 33-84 years). Tumors were more 
frequently located in the pancreatic head (15 cases) followed by the tail (12 cases) and the body 
region (12 cases). The mean size was 8 cm with a range between 1.6 and 29 cm. 35 out of 39 (89%) 
cases were pure ACCs, while four cases showing a neuroendocrine cell population >30% were 
defined as mixed acinar-neuroendocrine carcinomas (MANECs) [3]. The mean follow-up time was 
33 months (range 6-135 months). Twenty-seven patients died of disease after a mean follow-up 
time of 18.6 months, while 11 patients were alive at the last follow-up control (mean follow-up 
time of 67.5 months). One patient was lost to follow-up. 
Six cases (15.3%) showed nuclear immunoreactivity for c-myc, in a cell population ranging 
from 10 to 80% neoplastic cells (Figure 1). 
All 39 cases were scored for both c-MYC amplification (Figure 2A) and chromosome 8 
polysomy (Figure 2B): in detail, 20 ACCs had clones with different polysomies of chromosome 8 in 
absence of c-MYC amplification, 5 cases had one amplified clone and other clones with 
chromosome 8 polysomy. The remaining 14 cases were diploid for chromosome 8 and lacked c-
MYC amplification. FISH data of five c-MYC amplified cases are reported in Table 2. The clones with 
c-MYC amplification ranged from 33.1 to 77.4% of neoplastic cells. The ratio of c-MYC and 
chromosome 8 centromere ranged from 2.22 to 2.87 indicating presence of low level of c-MYC 
amplification in all cases. Polysomic cases showed different level of polysomies ranging from 3 to 
10 chromosomes 8 resulting in gain of MYC copies. Figure 2B shows a polysomic ACC showing 
nuclei  with 6 to  10 chromosome 8.  Interestingly, all MANECs showed c-MYC amplification and/or 
polysomy, which were observed in 19 out 35 (54%) pure ACCs. Four out the 39 cases investigated 
showed simultaneous c-MYC amplification/polysomy and a nuclear protein expression. As in most 
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cases of mixed acinar-neuroendocrine carcinomas [3, 5], the two components were not clearly 
separated or identifiable on morphological analysis and their identification was performed using 
immunohistochemistry. 
c-myc immunoreactivity as well as c-MYC amplification and/or chromosome 8 polysomy 
were not statistically associated with prognosis (p=0.04) (Figure 3). 
 
DISCUSSION 
The molecular signature of ACCs is different from that of pancreatic ductal 
adenocarcinomas and neuroendocrine neoplasms, and more frequently includes alterations in the 
APC/β-catenin pathway, while gene alterations frequently involved in ductal adenocarcinomas like 
mutations in KRAS, DPC4, p16, are absent or very rarely present [1, 15]. Alterations of TP53 gene 
(mutation of one allele and loss of the other allele) were recently found to be associated with 
worse survival [8] suggesting the possibility that specific subtypes of ACC may show specific 
molecular features with prognostic relevance. In this context, the recent identification that a 
subset of ACC shows c-MYC amplification [9] has suggested us to explore the prognostic role of c-
MYC alterations in pancreatic ACCs. 
c-MYC, whose function is tightly controlled by growth factor-dependent signals in normal 
adult cells [16, 17], plays a pivotal role in organogenesis and, in particular, in pancreatic acinar cell 
development and maturation [18]. However, its expression can be deregulated and enhanced via 
multiple mechanisms in tumor cells and is implicated in the pathogenesis, progression and 
aggressiveness of several human tumors. In particular, c-MYC protein expression and c-MYC gene 
activation by amplification have been found to be associated with tumor aggressiveness and poor 
prognosis of several cancers [11, 12, 16, 19, 20] including pancreatic ductal adenocarcinoma 
(PDAC) [10, 11]. Most of genetic and epigenetic alterations playing a role in the pathogenesis and 
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progression of PDACs involve c-MYC activations. c-MYC overexpression occurs in about 40% of 
advance PDACs, although comprehensive genetic analysis demonstrated that c-MYC is generally 
amplified at low levels [21]. Mechanisms involved in c-MYC deregulation in PDACs include genetic 
events or transcriptional, post-transcriptional signaling, or post-translational mechanisms. Genetic 
aberrations include mutation of the TGFβ-inhibitory elements controlling c-MYC promoter or c-
MYC amplification. Transcriptional mechanisms include the activation of transcription factors 
inducing c-MYC transcription or enhancement of c-MYC transcriptional elongation by CDK9-
mediated phosphorylation of RNA-polymerase. Alterations in post-transcriptional signaling include 
the attenuation of c-MYC-inhibiting miRNAs in absence of TP53 functions; post-translational 
mechanisms include CK2-mediated phosphorylation of c-MYC, which prevents proteasome 
degradation resulting in the reduction of c-MYC ubiquitination and degradation [10]. 
In 20 cases of our series we found chromosome 8 polysomy in absence of c-MYC 
amplification and in five cases both c-MYC amplification and chromosome 8 polysomy. This result 
suggests that c-MYC activation by gene amplification and/or polysomy is involved in the 
pathogenesis of at least a subset of ACCs. Interestingly, we found that all MANECs showed c-MYC 
amplification and/or polysomy which, on the contrary, were observed in only 54% of pure ACCs. In 
this context, it is interesting to recall that c-MYC has been found to regulate neuroendocrine trans-
differentiation of prostate adenocarcinoma resulting in the formation of the aggressive 
neuroendocrine-differentiated subtype [22-25]. In addition, c-MYC has been demonstrated to play 
a pivotal role in regulating ductal-neuroendocrine plasticity of pancreatic ductal adenocarcinoma 
leading to a neuroendocrine differentiation, which contributes to poor outcome and therapeutic 
resistance [26]. Taking together these findings may suggest that activation of c-MYC may lead to 
an acinar-neuroendocrine differentiation responsible of MANEC development. Starting from this 
observation, further studies are needed to confirm this hypothesis. 
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In general, we have found low level of c-MYC amplification in our series and this may 
explain the discordance observed between FISH and immunohistochemistry considering that the 
latter is a less sensitive method. Immunohistochemical expression of MYC seems to predict well c-
MYC alterations when more than 50% of nuclei are MYC positive [27]. In our series, among the five 
cases immunoreactive for MYC only two showed more than 50% of positive nuclei and both cases 
showed c-MYC polysomy. 
Regarding a possible prognostic role of c-MYC alterations, it is worth noting that pancreatic 
ACCs and MANECs are a group of aggressive carcinomas showing poor prognosis with 5-year 
survival rates ranging between 25 and 50%. To date, tumor stage seems to be the only 
prognosticator in resectable cases [5]. However, among resected cases the search for prognostic 
factors useful to stratify patients in different prognostic categories is a hot topic in pancreatic 
pathology. To the best of our knowledge, there are no  prognostic factors for surgical resected 
pancreatic ACCs and MANECs, although in recent years several attempts have been made to 
search for them. One of our aims was to check whether c-MYC amplification could be used as 
prognostic marker. Although we have observed a trend of worse survival in patients with c-MYC 
amplification than in patients without it we did not find a statistical meaning. 
In conclusion, our study demonstrates that a subset of ACCs show c-MYC alterations 
including gene amplification and chromosome 8 polysomy. Although they are not associated with 
a different prognostic signature, the fact that these alterations are present in all MANECs suggests 
a role in the acinar-neuroendocrine differentiations possibly involved in the pathogenesis of 
MANECs. 
 
Author contributions: Design and conception: SLR, BB, MGT; Data gathering and analysis: SLR, BB, 
MGT, AV, LZ, KN, LA, PB, AS, FS; Manuscript preparation: SLR, MGT, FS. 
10 
 
All authors have read and approved the final version of this manuscript. 
 
Compliance with ethical standard: This study was performed according to the clinical standards of 
the 1975 and 1983 Declaration of Helsinki and was approved by the Ethical Committee of the 
Ospedale di Circolo (ASST Sette Laghi), Varese, Italy (n.1277/10). 
 
Conflict of interest: The authors declare that they have not conflict of interest. 
 
 
REFERENCES 
1. La Rosa S, Sessa F, Capella C (2015) Acinar cell carcinoma of the pancreas: overview of 
clinicopathologic features and insights into the molecular pathology. Front Med 2:41. 
http://doi: 10.3389/fmed.2015.00041 
2. La Rosa S, Sessa F, Uccella S (2016) Mixed neuroendocrine-nonneuroendocrine neoplasms 
(MiNENs): unifying the concept of a heterogeneous group of neoplasms. Endocr Pathol 
27:284-311. doi: 10.1007/s12022-016-9432-9 
3. Klöppel G, Couvelard A, Hruban RH, Klimstra DS, Komminoth P, Osamura RY, Perren A, Rindi G 
(2017) Neoplasms of the neuroendocrine pancreas. Introduction. In: Lloyd RV, Osamura RY, 
Klöppel G, Rosai J (eds) WHO classification of tumours of endocrine organs. IARC Press, Lyon, 
pp 211-214 
4. Wisnoski NC, Townsend CM Jr, Nealon WH, Freeman JL, Riall TS (2008) 672 patients with 
acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic 
adenocarcinoma. Surgery 144:141-148. doi: 10.1016/j.surg.2008.03.006 
11 
 
5. La Rosa S, Adsay V, Albarello L, Asioli S, Casnedi S, Franzi F, Marando A, Notohara K, Sessa F, 
Vanoli A, Zhang L, Capella C (2012) Clinicopathologic Study of 62 acinar cell carcinomas of the 
pancreas: insights into the morphology and immunophenotype and search for prognostic 
markers. Am J Surg Pathol 36:1782-1795. doi: 10.1097/PAS.0b013e318263209d 
6. Furlan D, Sahnane N, Bernasconi B, Frattini M, Tibiletti MG, Molinari F, Marando A, Zhang L, 
Vanoli A, Casnedi S, Adsay V, Notohara K, Albarello L, Asioli S, Sessa F, Capella C, La Rosa S 
(2014) APC alterations are frequently involved in the pathogenesis of acinar cell carcinoma of 
the pancreas, mainly through gene loss and promoter hypermethylation. Virchows Arch 
464:553-564. doi: 10.1007/s00428-014-1562-1 
7. Chmielecki J, Hutchinson KE, Frampton GM, Chalmers ZR, Johnson A, Shi C, Elvin J, Ali SM, 
Ross JS, Basturk O, Balasubramanian S, Lipson D, Yelensky R, Pao W, Miller VA, Klimstra DS, 
Stephens PJ (2014) Comprehensive genomic profiling of pancreatic acinar cell carcinomas 
identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. Cancer Discov 
4:1398-1405. doi: 10.1158/2159-8290.CD-14-0617 
8. La Rosa S, Bernasconi B, Frattini M, Tibiletti MG, Molinari F, Furlan D,Sahnane N, Vanoli A, 
Albarello L, Zhang L, Notohara K, Casnedi S, Chenard MP, Adsay V, Asioli S, Capella C, Sessa F 
(2016) TP53 alterations in pancreatic acinar cell carcinoma: new insights into the molecular 
pathology of this rare cancer. Virchows Arch 468:289-296. doi: 10.1007/s00428-015-1882-9 
9. Bergmann F, Aulmann S, Sipos B, Kloor M, von Heydebreck A, Schweipert J, Harjung A, Mayer 
P, Hartwig W, Moldenhauer G, Capper D, Dyckhoff G, Freier K,Herpel E, Schleider A, 
Schirmacher P, Mechtersheimer G, Klöppel G, Bläker H (2014) Acinar cell carcinomas of the 
pancreas: a molecular analysis in a series of 57 cases. Virchows Arch 465:661-672. doi: 
10.1007/s00428-014-1657-8 
12 
 
10. Hessmann E, Schneider G, Ellenrieder V, Siveke JT (2016) MYC in pancreatic cancer: novel 
mechanistic insights and their translation into therapeutic strategies. Oncogene 35:1609-18. 
doi: 10.1038/onc.2015.216 
11. Nesbit CE, Tersak JM, Prochownik EV (1999) MYC oncogenes and human neoplastic disease. 
Oncogene 18:3004-3016 doi: 10.1038/sj.onc.1202746 
12. Skoudy A, Hernández-Muñoz I, Navarro P (2011) Pancreatic ductal adenocarcinoma and 
transcription factors: role of c-Myc. J Gastrointest Cancer 42:76-84. doi: 10.1007/s12029-011-
9258-0 
13. Hastings RJ, Bown N, Tibiletti MG, et al (2016) Guidelines for cytogenetic investigations in 
tumours. Eur J Hum Genet 24:6-13. doi:10.1038/ejhg.2015.35 
14. Shaffer LG, McGowan-Jordan J, Schmid M (2013) ISCN an international system for human 
cytogenetic nomenclature. Published in collaboration with 'Cytogenetic and Genome 
Research'. Karger, Basel ISBN:978-3-318-02253-7 
15. Jäkel C, Bergmann F, Toth R, Assenov Y, van der Duin D, Strobel O, Hank T, Klöppel G, Dorrell 
C, Grompe M, Moss J, Dor Y, Schirmacher P, Plass C, Popanda O, Schmezer P (2017) Genome-
wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations 
in genome stability. Nat Commun 8:1323. doi: 10.1038/s41467-017-01118-x 
16. Eilers M, Eisenman RN (2008) Myc's broad reach. Genes Dev 22:2755-2766. doi: 
10.1101/gad.1712408 
17. Meyer N, Penn LZ (2008) Reflecting on 25 years with MYC. Nat Rev Cancer 8:976-990. doi: 
10.1038/nrc2231 
18. Sánchez-Arévalo Lobo VJ, Fernández LC, Carrillo-de-Santa-Pau E, et al (2018) c-Myc 
downregulation is required for preacinar to acinar maturation and pancreatic homeostasis. 
Gut 67:707-718. doi: 10.1136/gutjnl-2016-312306 
13 
 
19. Dang CV (2012) MYC on the path to cancer. Cell 149:22-35. doi: 10.1016/j.cell.2012.03.003 
20. Kress TR, Sabò A, Amati B (2015) MYC: connecting selective transcriptional control to global 
RNA production. Nat Rev Cancer 15:593-607. doi: 10.1038/nrc3984 
21. Schleger C, Verbeke C, Hildenbrand R, Zentgraf H, Bleyl U (2002) c-MYC activation in primary 
and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical 
significance. Mod Pathol 15:462-469 
22. Beltran H, Rickman DS, Park K, et al (2011) Molecular characterization of neuroendocrine 
prostate cancer and identification of new drug targets. Cancer Discov 1:487-495. doi: 
10.1158/2159-8290 
23. Dardenne E, Beltran H, Benelli M, et al (2016) N-Myc induces an EZH2-mediated 
transcriptional program driving neuroendocrine prostate cancer. Cancer Cell 30:563-577. doi: 
10.1016/j.ccell.2016.09.005 
24. Wang J, Kim J, Roh M, Franco OE, Hayward SW, Wills ML, Abdulkadir SA (2010) Pim1 kinase 
synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene 29:2477-2487. doi: 
10.1038/onc.2010.10 
25. Lee JK, Phillips JW, Smith BA, et al (2016) N-Myc drives neuroendocrine prostate cancer 
initiated from human prostate epithelial cells. Cancer Cell 29:536-547. doi: 
10.1016/j.ccell.2016.03.001 
26. Farrell AS, Joly MM, Allen-Petersen BL, et al (2017) MYC regulates ductal-neuroendocrine 
lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and 
chemoresistance. Nat Commun 8:1728. doi: 10.1038/s41467-017-01967- 
27. Nwanze J, Siddiqui MT, Stevens KA, Saxe D, Cohen C (2017) MYC immunohistochemistry 
predicts myc rearrangements by FISH. Front Oncol 7:209. doi: 10.3389/fonc.2017.00209 
14 
 
FIGURE LEGENDS 
Figure 1. c-myc nuclear immunoreactivity in the majority of neoplastic cells of a pancreatic acinar 
cell carcinoma. 
Figure 2. FISH analysis using MYC probe (red signals) and chromosome 8 centromere 
(green signals). A subgroup of acinar cell carcinomas and all mixed acinar-neuroendocrine 
carcinomas showed c-MYC amplification (A) and/or chromosome 8 polysomy (B). 
Figure 3. C-myc protein expression (A) was not statistically associated with prognosis as well as c-
MYC amplification (B), chromosome 8 polysomy (C) or their combination (D). 
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Table 1. Clinico-pathologic and FISH features of the 39 ACCs/MANECs investigated 
 
Case Sex Age Type Site Size Follow-up MTS MYC protein c-MYC Chr. 8 
     (cm) (months)  expression amplification polysomy* 
           
1 M 49 ACC B/T 6,2 DOD (24) no 0 no no 
2 M 51 ACC H 7,5 DOD (6) yes 0 no 22% 
3 M 57 ACC B/T 14 AWD (56) no 0 no no 
4 M 44 ACC B/T 13 AWD (36) no 0 no 50% 
5 M 70 ACC B 5 AFD (135) no 0 R=2.87 25% 
6 M 70 ACC B/T 25 DOD (6) yes 15 R=2.66 38% 
7 M 74 ACC T 4 AFD (89) no 0 no no 
8 F 75 ACC T 3,8 DOD (16) no 0 no 42.5% 
9 M 63 ACC H 3 DOD (14) no 0 no 54.5% 
10 M 69 MANEC H 7 DOD (9) no 0 R=2.22 54.8 
11 F 37 MANEC B 6,2 AFD (111) no 10 no 66% 
12 M 71 ACC B/T 7 AFD (84) no 0 no no 
13 M 47 ACC T 6 AFD (84) no 0 no 97% 
14 F 63 ACC T 10 DOD (12) yes 10 no no 
15 M 76 ACC H 4 DOD (36) yes 0 no no 
16 M 49 ACC H 1,6 DOD (79) no 0 no no 
17 M 55 MANEC H 5 DOD (6) yes 0 R=2.83 45% 
18 M 67 ACC T 29 DOD (6) yes 80 no 22.3% 
19 M 67 ACC T 3 DOD (6) yes 0 no no 
20 M 71 ACC H 5 DOD (26) yes 0 no 100% 
21 M 62 ACC H 4,5 AFD (24) no 0 no no 
22 M 53 ACC H NA L yes 0 no no 
23 F 42 ACC B/T 10 DOD (22) yes 0 no 93% 
24 M 60 ACC H 5 AFD (76) no 0 no 100% 
25 F 45 ACC H 11,5 DOD (16) no 0 no no 
26 M 70 ACC B 8 DOD (19) no 0 no 20.6 
27 M 47 ACC T 10 DOD (10) yes 0 no 15% 
28 M 59 ACC H 3 DOD (22) yes 0 R=2.77 no 
29 M 53 ACC T 2,5 DOD (8) yes 0 no no 
30 F 69 ACC B 5 DOD (30) no 0 no 13.5% 
31 F 72 ACC B/T 8 DOD (20) no 0 no 77% 
32 M 55 ACC T 2 DOD (34) yes 30 no no 
33 M 84 ACC B/T 7 DOD (9) no 0 no 85% 
34 M 60 ACC H 4 DOD (13) no 0 no no 
35 M 46 MANEC T 16 DOD (12) yes 0 no 41.5% 
36 M 82 ACC T 11 DOD (26) yes 60 no 36.4% 
37 F 50 ACC T 4 AWD (32) yes 0 no 100% 
38 F 33 ACC H 8 DOD (16) no 0 no 62% 
39 F 61 ACC H 3 AFD (16) no 0 no 77% 
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MTS: metastasis; F: female; M: male; ACC: acinar cell carcinoma; MANECs: mixed 
acinar-neuroendocrine carcinoma; AFD: alive free of disease; AWD: alive with 
disease; DOD: died of disease; L: lost at follow-up; H: head; B: body; T: tail; R: 
ratio of c-MYC and chromosome 8 centromere; *: percentage of polysomic cells; 
NA: not available.
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Table 2. Correlation between c-MYC amplification and chromosome 8 polysomy 
in acinar cell carcinomas. 
 
case Amplified cells 
(%) 
Ratio 
MYC/CEN 
MYC 
Mean value of 
signals 
CEN 8 
Mean value of 
signals 
5 38.5 2.87 6.11 2.13 
6 60.2 2.66 5.49 2.07 
10 33.1 2.22 5.09 2.29 
17 77.4 2.83 6.74 2.38 
28 44.0 2.77 4.68 1.69 
CEN: centromere 
 
 
 
 



